The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Thu., Mar. 28, 6:17 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #9. Charles River Laboratories CRO Services Division of Galapagos NV

Acquirer: Charles River Laboratories (NYSE:CRL)
Acquiree: CRO Services Division of Galapagos NV
Details: Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it has completed the previously announced acquisition of the CRO services division of Galapagos NV (Euronext: GLPG), which includes both Argenta and BioFocus. The acquisition positions Charles River as a full service, early-stage contract research organization (CRO), with integrated in vitro and in vivo capabilities from target discovery through preclinical development.

Charles River Laboratories International is a full service, non-clinical global drug development partner. Co. has laboratory animal medicine and science (research model technologies) to develop a portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that supports its clients from target identification through non-clinical development. Co. also provides a suite of products and services to support its clients' manufacturing activities, including its contract development and manufacturing organization business. Co. has three reporting segments: Research Models and Services, Discovery and Safety Assessment and Manufacturing Solutions.

CRL SEC Filing Email Alerts Service


Open the CRL Page at The Online Investor »

Company Name: 
Charles River Laboratories International Inc.
Website: 
www.criver.com
Sector: 
Biotechnology
Number of ETFs Holding CRL: 
82
Total Market Value Held by ETFs: 
$2.20B
Total Market Capitalization: 
$13.64B
% of Market Cap. Held by ETFs: 
16.15%
 

Open the CRL Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree CRL Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (3.20 out of 4)
40th percentile
(ranked lower than approx. 60% of all stocks covered)

Analysts' Target Price:
CRL Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 9 of 83 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.